Reed focuses on new technology development, including clinical trials and investment start-up companies. He has been covering medical technology since joining The Gray Sheet in 2000, and also covered cardiovascular technology for theheart.org and drug industry compliance issues for HCPro. Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.
Latest From Reed Miller
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.
Edwards Lifesciences is ramping up US commercialization of its Pascal Precision mitral valve transcatheter edge-to-edge repair device, the first US competitor for Abbott’s MitraClip. The FDA approved Pascal Precision earlier than the company expected, based on results of the CLASP IID trial.
Results of the CLASP IID trial showed Edwards’ Pascal mitral valve repair system was non-inferior for safety and effectiveness compared to Abbott’s MitraClip device.
Medtech executives at the the Wells Fargo Healthcare Conference talked about the challenges facing them now, including hospital staffing shortages, supply chain constraints, and inflation. Here are some of the highlights from their comments
The company received a $5m grant from the Bill & Melinda Gates Foundation to improve access to medical imaging across Sub-Saharan Africa.
Bloomberg reported that Baxter is exploring options to divest its renal care services and hemodialysis businesses to focus more resources on higher-growth businesses and pay down the debt it took on to acquire Hillrom last year.